We recently compiled a list of the Billionaire Prem Watsa’s Top 15 Long-Term Stock Picks. In this article, we are going to ...

Co., Inc. (NYSE:MRK) and Eisai Co., Ltd. (TYO:4523) have announced the latest outcomes from their Phase 3 LEAP-015 trial, ...

Merck & Co. and Eisai reported mixed results from a late-stage study of the cancer drugs Keytruda and Lenvima in patients with certain types of gastroesophageal cancer.

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other large-cap value stocks. Why is this Portfolio Manager Cautiously Optimistic? The market ...

Department of Health and Human Services (HHS) secretary nominee Robert F. Kennedy Jr. plans to continue to receive referral fees from a law firm that is suing pharma powerhouse Merck & Co. | ...

In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Merck & Company (MRK – Research Report). The ...

Robert F. Kennedy Jr. would retain legal fees earned from litigation against drugmaker Merck if he is confirmed as President ...

Merck (MRK) and Esai (ESALF) (ESAIY) announce a mixed outcome in their Phase 3 LEAP-015 trial for Keytruda/ Lenvima regimen ...

Merck and Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end ...

Merck KGaA (Merck) and Opentrons Labworks have announced a partnership to automate assay kits on a ‘custom’ Opentrons Flex ...

Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve ...

Discover why Merck presents a compelling long-term investment opportunity with its discounted valuation, robust pipeline, and ...